An Lin, Lin Yuefang, Li Leyan, Kong Muyan, Lou Yanmei, Wu Jinjun, Liu Zhongqiu
Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International Institute for Translational Chinese Medicine, School of Pharmaceutical Science, Guangzhou University of Chinese Medicine, Guangzhou, China.
Front Pharmacol. 2021 Jan 22;11:618262. doi: 10.3389/fphar.2020.618262. eCollection 2020.
Hepatic fibrosis (HF) represents the excessive wound healing where an excess amount of connective tissues is formed within the liver, finally resulting in cirrhosis or even hepatocellular carcinoma (HCC). Therefore, it is significant to discover the efficient agents and components to treat HF, thus restraining the further progression of hepatopathy. (Fisch.) Bunge [also called Radix (AR)] is a famous herb in traditional Chinese medicine (TCM), which possesses a variety of biological activities and exerts good therapeutic effects in the treatment of HF. Flavonoids account for the major active ingredients related to the AR pharmacological effects. Total AR flavonoids have been proved to exert inhibitory effects on hepatic fibrosis. This study aimed to further undertake network pharmacology analysis coupled with experimental validation and molecular docking to investigate the effects and mechanism of multiple flavonoid components from AR against liver fibrosis. The results of the network pharmacology analysis showed that the flavonoids from AR exerted their pharmacological effects against liver fibrosis by modulating multiple targets and pathways. The experimental validation data showed that the flavonoids from AR were able to suppress transforming growth factor beta 1 (TGF-β1)-mediated activation of hepatic stellate cells (HSCs) and reduce extracellular matrix deposition in HSC-T6 cells via regulating the nuclear factor kappa B (NF-κB) signal transduction pathway. The results of the molecular docking study further showed that the flavonoids had a strong binding affinity for IκB kinase (IKKβ) after docking into the crystal structure. The above results indicated that, flavonoids possibly exerted the anti-inflammatory effect on treating HF by mediating inflammatory signaling pathways. The potential mechanism of these flavonoids against liver fibrosis may be related to suppression of the NF-κB pathway through effective inhibition of IKKβ. This study not only provides a scientific basis for clarifying the effects and mechanism of AR flavonoids against liver fibrosis but also suggests a novel promising therapeutic strategy for the treatment of liver fibrosis.
肝纤维化(HF)是一种过度的伤口愈合过程,肝脏内会形成过量的结缔组织,最终导致肝硬化甚至肝细胞癌(HCC)。因此,发现有效的治疗HF的药物和成分,从而抑制肝病的进一步发展具有重要意义。(Fisch.)Bunge [也称为黄芪(AR)] 是传统中药(TCM)中的一种著名草药,具有多种生物活性,在治疗HF方面发挥着良好的治疗作用。黄酮类化合物是与AR药理作用相关的主要活性成分。已证明总AR黄酮对肝纤维化有抑制作用。本研究旨在进一步进行网络药理学分析,并结合实验验证和分子对接,以研究AR中多种黄酮类成分抗肝纤维化的作用及机制。网络药理学分析结果表明,AR中的黄酮类化合物通过调节多个靶点和途径发挥其抗肝纤维化的药理作用。实验验证数据表明,AR中的黄酮类化合物能够抑制转化生长因子β1(TGF-β1)介导的肝星状细胞(HSCs)激活,并通过调节核因子κB(NF-κB)信号转导途径减少HSC-T6细胞中的细胞外基质沉积。分子对接研究结果进一步表明,黄酮类化合物对接入晶体结构后对IκB激酶(IKKβ)具有很强的结合亲和力。上述结果表明,黄酮类化合物可能通过介导炎症信号通路对治疗HF发挥抗炎作用。这些黄酮类化合物抗肝纤维化的潜在机制可能与通过有效抑制IKKβ抑制NF-κB途径有关。本研究不仅为阐明AR黄酮类化合物抗肝纤维化的作用及机制提供了科学依据,也为肝纤维化的治疗提出了一种新的有前景的治疗策略。